DRUG LEGALIZATION SERIES
PART 6
If you’re new to the series, start here.

Why Tusi (Pink Cocaine), Fentanyl Additives, and THC Analogues Prove Enforcement Can’t Keep Up

In Part 1, we addressed the myth that punishment leads to recovery. In Part 5, we showed how prohibition manufactures chaos—overdose risk, violence, and a black market that rewards the worst actors.

Part 6 is the practical follow‑through: the drug supply is evolving faster than enforcement can react, and it always will. If we want safer communities, we need drug legalization and regulation built around product standards, testing, licensing, and prevention—not an endless game of chemical catch‑up.

Here’s the pattern we can’t ignore:

• Marketing is replacing labeling (street names, colors, branding)
• Chemistry is replacing consistency (new mixes, new additives, new analogues)
• Enforcement is always behind (by the time something is identified, it’s already circulating)

That’s why people are dying from drugs they didn’t choose—and often from effects responders can’t easily reverse.

This isn’t an argument that drugs are harmless. It’s the opposite. It’s an argument that illegality guarantees an unsafe supply chain, and regulation is how you impose safety rules on reality.

The core problem: in an illegal market, branding replaces standardization

In a regulated industry (food, alcohol, pharmaceuticals), three things are non‑negotiable:

1. You know what the product is
2. You know how strong it is
3. If it harms people because it was misrepresented or contaminated, someone is accountable

Prohibition removes those guardrails. It creates a market where:

• “Quality” becomes a rumor
• “Dose” becomes a guess
• “Ingredient lists” don’t exist
• Liability disappears
• The easiest way to compete is to change the product, not improve it

Nowhere is that clearer than tusi.

What is tusi (pink cocaine), and why it’s a warning sign for the future

Tusi (“pink cocaine”) is the perfect example of drug marketing outrunning drug reality.

DEA describes “pink cocaine” as a dyed powdered mixture (often called tusi), and notes that it evolved from an original association with 2C‑B into a variable “drug cocktail” sold under a recognizable brand identity. [1]

Peer‑reviewed research goes further: tusi is often a polydrug product with inconsistent contents, and it frequently contains neither cocaine nor 2C‑B despite the names people use for it. [2] Earlier research similarly describes tusi as a “ketamine concoction” whose contents and risks vary widely. [3]

That’s the operational point:

If the market is illegal, the market cannot be standardized.
Not by speeches. Not by slogans. Not by arrests.

Tusi’s “innovation” is simple: take a mix of drugs, add food dye, sell it as a vibe.

A color becomes “quality control.”
A nickname becomes “labeling.”

And that’s not a fringe case—it’s where the supply is going.

Fentanyl adulterants: xylazine and medetomidine are making overdoses harder to treat

We’re now in an era where it’s not just “fentanyl.” It’s fentanyl plus additives—often sedatives that change the entire overdose profile.

Xylazine fentanyl is a problem

CDC warns that xylazine (a non‑opioid sedative) is increasingly found in the illegal drug supply, often in combination with fentanyl, and that it can slow breathing and heart rate—making it especially dangerous when combined with opioids. [4]

DEA has also issued a public safety alert about fentanyl mixed with xylazine—again underscoring that the supply is shifting in ways the public did not consent to. [5]

Critical practical point: xylazine is not an opioid. So, naloxone reverses opioid effects, but it does not reverse xylazine’s sedative effects. The right response still includes naloxone (because fentanyl is often involved), but overdose management becomes more complicated and often requires rescue breathing and clinical care. [4]

Medetomidine: the “next additive” proves why enforcement is always behind

Medetomidine is another veterinary sedative. It’s now appearing as an adulterant in the illegal opioid supply, and it is producing clinical presentations that look different than the “standard” opioid overdose picture.

CDC’s MMWR reports a Chicago cluster where medetomidine‑involved overdoses were marked by bradycardia and lack of response to naloxone, and fentanyl was present in all blood specimens and drug samples that tested positive for medetomidine. [6]

CDC’s MMWR also describes a withdrawal syndrome in Philadelphia where fentanyl withdrawal was complicated by profound autonomic dysfunction, resistant to medications that had worked for fentanyl and xylazine withdrawal, but responsive to dexmedetomidine. [7]

This is the chemical arms race in real time:

• The supply changes
• The clinical picture changes
• Treatment protocols have to change
• Public warning systems catch up after harm is already happening

That lag is built into prohibition.

Drug analogues and NPS: why “we’ll ban the next one” will never work

Even if we solved today’s mixture problem, we still face the analogue problem: new compounds, new variants, new “legal highs,” new opioids.

UNODC’s Early Warning Advisory reports that 1,396 unique new psychoactive substances have been reported globally, and that 2024 reached a record 688 unique NPS reported in a single year. [8]

That number matters because it describes the reality enforcement is up against:

You can’t freeze chemistry.
You can only decide whether chemistry is happening in a regulated environment or an unregulated one.

Nitazenes: another example of dangerous novelty reaching communities

CDC has documented nitazene‑involved fatal overdoses (Tennessee data), showing how new synthetic opioids can emerge and become lethal before public awareness, surveillance, and clinical preparedness catch up. [9]

UNODC has also warned of the growing availability and spread of nitazenes globally. [10]

THC analogues: delta‑8 products show what happens when policy creates loopholes instead of standards

Some people hear “THC analogues” and think it’s unrelated to fentanyl.

It’s the same supply‑chain lesson: if you allow an intoxicant market without clear standards, marketing fills the gap.

CDC issued a Health Alert noting that the rise of delta‑8 THC products increased availability of psychoactive cannabis products, and warned that variations in product content, manufacturing, labeling, and misunderstandings about psychoactive properties can lead to unexpected effects. [11]

FDA has warned that delta‑8 THC risks have not been evaluated or approved for safe use and reported adverse events in people who consumed delta‑8 products. [12]

And the FTC, alongside FDA, has sent cease‑and‑desist letters to companies selling delta‑8 edibles in packaging that mimics foods children eat—because when standards are weak, “branding” becomes a safety hazard. [13]

This is the exact point of regulation:

• not “ban everything”
• set rules and enforce product standards
• prevent child‑appealing marketing
• require labeling and testing
• create accountability

Why enforcement can’t deliver standardization

Enforcement can seize drugs and arrest people. It can disrupt supply temporarily. It can raise prices. It can move markets around.

But it cannot do what regulation does:

• require batch testing
• mandate accurate labels
• ban specific contaminants and enforce thresholds
• create licensing and traceability
• operate recalls
• impose civil liability on producers and sellers

R Street’s work on the evolving, increasingly toxic illicit drug supply makes the same underlying point: the illegal supply is volatile, adulterated, and dangerous—and harm reduction and regulatory thinking become essential in that environment. [14]

If your goal is fewer overdoses and fewer adverse events, you can’t get there by pretending the supply chain doesn’t exist.

You have to govern it.

What regulation actually looks like (and what it is NOT)

Regulation is not permissiveness. It’s structure.

A serious “adult replacement” for the drug war would include, at minimum:

1. Licensing (production, distribution, retail)
2. Mandatory testing (identity, potency, contaminants; updated panels as new compounds appear)
3. Transparent labeling (dose, contents, warnings)
4. Track‑and‑trace (supply chain visibility; diversion control)
5. Marketing restrictions (especially youth‑appealing packaging and claims)
6. Rapid surveillance and public alerts (real-time monitoring, not year‑late reports)
7. Earmarked revenue (prevention, education, treatment, recovery housing, reentry continuity)

In other words: treat drugs like every other risky product category we regulate for public safety. See Part 1.5 for definitions of legalization vs. decriminilization vs. regulation.

The real choice: chemical roulette or product standards

Tusi, xylazine, medetomidine, nitazenes, and THC analogues all point to the same conclusion:

We’re not in a “drug problem.” We’re in a product‑safety vacuum.

As long as the market is underground (or loophole‑driven), the incentives reward:

• novelty over consistency
• branding over accuracy
• potency over predictability
• speed over safety

Drug legalization and regulation doesn’t make addiction disappear. But it can stop the system from actively making the supply more chaotic, more deceptive, and more lethal.

That’s what making communities safer actually means: fewer unknowns, fewer surprises, and fewer people dying from chemistry they didn’t consent to.

If you want to follow the full series as it publishes, visit the blog.
If you prefer audio conversations on recovery, reentry, and purpose, check the podcast.
And if you want the longer story behind why I write about this, start here.

FAQ

Is tusi (pink cocaine) real cocaine?

Usually, no. DEA describes tusi “pink cocaine” as a dyed powdered mixture, and research describes it as a variable polydrug product that often contains neither cocaine nor 2C‑B. [1][2][3]

Does naloxone work if xylazine is involved?

Naloxone reverses opioid effects (like fentanyl), but xylazine is a non‑opioid sedative. CDC notes xylazine is increasingly found mixed with fentanyl; overdose response may require rescue breathing and clinical care even after naloxone, which may be ineffective for xylazine fentanyl. [4]

What is medetomidine and why does it matter?

Medetomidine is a veterinary sedative appearing in the illegal opioid supply. CDC reports medetomidine overdoses mixed with opioids display clinical features including bradycardia and lack of response to naloxone and reports a related withdrawal syndrome in Philadelphia. [6][7]

Why do new drug analogues keep appearing?

Because illicit markets adapt. UNODC reports a large and growing number of new psychoactive substances globally, showing how quickly new compounds emerge. [8]

Are delta‑8 THC products regulated?

Public health agencies have warned they are not consistently regulated like approved consumer products. CDC issued a HAN advisory on delta‑8 product risks and variability, FDA has warned about adverse events and lack of approval, and FTC/FDA have intervened in cases involving child‑appealing “copycat” packaging. [11][12][13]

References

1. DEA — “Pink Cocaine” (tusi described as dyed mixture; evolved into variable cocktail).
2. Fitzgerald ND, Abukahok N, Palamar JJ. “When pink powders shift the drug landscape: tusi (‘pink cocaine’) and other colored powders.” International Journal of Drug Policy (author manuscript in PMC).
3. Palamar JJ. “Tusi: a new ketamine concoction complicating the drug landscape.” PubMed (2023).
4. CDC — “What You Should Know About Xylazine.”
5. DEA Public Safety Alert — “DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine.”
6. CDC MMWR — “Overdoses Involving Medetomidine Mixed with Opioids — Chicago, Illinois, May 2024.”
7. CDC MMWR — “Suspected Medetomidine Withdrawal Syndrome Among Fentanyl‑Exposed Patients — Philadelphia, Pennsylvania, Sept 2024–Jan 2025.”
8. UNODC Early Warning Advisory — Record high of 688 unique NPS reported in 2024; 1,396 unique NPS reported overall.
9. CDC MMWR — “Nitazene‑Related Deaths — Tennessee, 2019–2021.”
10. UNODC Early Warning Advisory — “Increasing availability of nitazenes calls for global response.”
11. CDC Health Alert Network (HAN 00451) — delta‑8 THC products, variability, adverse events.
12. FDA — “5 Things to Know about Delta‑8 THC.”
13. FTC press release (with FDA) — cease‑and‑desist letters over delta‑8 edibles packaged like children’s foods.
14. R Street Institute — “An Ever‑Changing, Increasingly Toxic Drug Supply Makes Harm Reduction Essential.”

Previous                                                                                                                                                 Next